Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.12.008Source: DataRank Database

Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer is a research paper published in Clinical Lung Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 2.52)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Joshua E. Reuss ORCID,Anna Crawford ORCID,Brian Neelon ORCID,Jun O. Liu ORCID,Julie R. Brahmer ORCID

Live enrichment

PubMed:39818516 PMC:PMC12037305 OpenAlex:https://openalex.org/W4405775352

National Cancer Institute

Grant: R00 CA246097

National Cancer Institute

Grant: P30 CA138313

Centers for Disease Control and Prevention

Grant: 1NU58DP007156

NCI NIH HHS

Grant: HHSN261201800015C

NCI NIH HHS

Grant: HHSN261201800009I

NCI NIH HHS

Grant: HHSN261201800015I

NCI NIH HHS

Grant: HHSN261201800032I

NCI NIH HHS

Grant: HHSN261201800009C

NCI NIH HHS

Grant: HHSN261201800032C

Massachusetts Department of Public Health

National Institutes of Health

University of Southern California

FWCI

2.52

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12037305/

publisherhttps://api.elsevier.com/content/article/PII:S1525730424002717?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730424002717?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2024.12.008

Fields of Study

Cancer, Lipids, and MetabolismCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisHumansCarcinoma, Non-Small-Cell LungHydroxymethylglutaryl-CoA Reductase InhibitorsAgedLung NeoplasmsMaleFemaleImmune Checkpoint InhibitorsRetrospective StudiesAged, 80 and overUnited StatesSEER ProgramMedicareSurvival RateFollow-Up Studies

MeSH Terms

Immune Checkpoint InhibitorsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesMedicareHumansLung NeoplasmsMaleRetrospective StudiesUnited StatesSurvival RateSEER ProgramHydroxymethylglutaryl-CoA Reductase Inhibitors

Keywords

MedicineLung cancerStatinOncologyCancer researchImmune systemHydroxymethylglutaryl-CoA Reductase InhibitorsCancerImmune checkpointInternal medicineImmunotherapyImmunologyMortalitySurvival analysisOlder AdultsRetrospective Cohort StudySeer-medicare

Sustainable Development Goals

SDG 0: Good health and well-being